Table 4.
Comparison of participants on antipsychotic monotherapy or polypharmacy on the basis of symptom profile, CPZeq, side-effect profile and functioning.
| Variable | Polypharmacy Mean (SD) |
Monotherapy Mean (SD) |
t/U | p |
|---|---|---|---|---|
| PANSS-P | 11.54 (6.25) | 11.16 (6.84) | −0.424 | 0.67 |
| PANSS-N | 16.18 (8.49) | 13.19 (5.93) | − 2.760 | 0.01 |
| PANSS-G | 28.06 (11.47) | 25.66 (10.21) | − 1.559 | 0.12 |
| PANSS-T | 55.73 (22.98) | 49.91 (19.39) | − 1.912 | 0.06 |
| GAF | 66.91 (23.03) | 73.49 (21.41) | −2.104 | 0.04 |
| LUNSERS | ||||
| Total | 18.87 (12.40) | 15.43 (11.22) | 2.056 | 0.04 |
| Extrapyramidal | 4.96 (4.93) | 4.54 (5.40) | 0.60 | 0.55 |
| Anticholinergic | 1.21 (2.02) | 1.51 (2.01) | −1.09 | 0.28 |
| Other autonomic | 1.78 (2.55) | 1.32 (1.93) | 1.40 | 0.17 |
| Allergic reactions | 0.52 (1.58) | 0.28 (0.91) | 1.19 | 0.24 |
| Psychic | 5.30 (4.61) | 4.99 (4.51) | 0.50 | 0.62 |
| Hormonal | 1.32 (1.84) | 1.70 (2.15) | −1.43 | 0.15 |
| Miscellaneous | 1.57 (1.79) | 1.47 (1.63) | 0.42 | 0.68 |
| Prescribed daily dose (CPZ Eq.) | 838.21 (471.58) | 288.18 (216.93) | 12.62 | 0.001 |
GAF, Global Assessment of Functioning Scale; LUNSERS, Liverpool University Side Effects Rating Scale; PANSS, Positive and Negative Syndrome Scale; SD, standard deviation.
Statistically significant values are highlighted in bold font.